FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP				
	STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPRO	DVAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5
	OMB Number: Estimated average burd

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Powell Lynne (Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX BCRX										[(Ch	neck all app Direc V Office	lationship of Reportin ck all applicable) Director Officer (give title		10% O	/ner
					01/	3. Date of Earliest Transaction (Month/Day/Year) 01/18/2019											Senior VP - CCO			
(Street) DURHA (City)		tate)	27703 (Zip)		-							Lin	e) X Form Form Perso	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - No	n-Deriv	ative	e Se	curit	ies Ad	cqui	ired, D	Disp	osed o	of, or	Bene	eficia	ly Owne	d			
1. Title of Security (Instr. 3)			Date	nsaction th/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		e,	Code (Instr.					(A) or 3, 4 and	Benefic Owned	es Formially (D) Following (I) (I		n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount		(A) or (D)	Price	Report Transa (Instr. 3	tion(s)			(Instr. 4)
Common	Stock ⁽¹⁾			01/18	3/2019	2019			М		2,000		A	\$3.2	2 2	2,000		D		
Common	Stock ⁽¹⁾			01/18	3/2019	9				S		2,000	0	D	\$9.4	\$9.4 0 D				
		٦	able II -	Deriva (e.g., p	tive s	Seci call:	uritie s, wa	s Acc	quire s, o	ed, Di	spo s, c	sed of onverti	, or E ble s	Benef securi	icially ties)	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date, Transac Code (In			of Der Sec Acc (A) Disp of (I	of E		6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	te ercisable		xpiration ate	Title	O N O	umber					
Emp. Stock Option (Right to Buy) ⁽¹⁾	\$3.22	01/18/2019			М			2,000	05/	/23/2017	05	5/23/2026	Comi		2,000	\$0	91,42	7	D	

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2018.

/s/ Alane P. Barnes, by power of attorney

01/23/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.